Using ultra-rapid insulin analogs in children and adolescents with type 1 diabetes mellitus

О.V. Bolshova, N.A. Sprinchuk

Abstract


Background. The purpose of the study was a retrospective comparative analysis of using insulin analogues of the prolonged and ultra-short action and human genetically engineered insulins of middle and short action in children and adolescents with type 1 diabetes mellitus (DM). Materials and methods. The influence of ultra-rapid insulin analog in comparison with human rapid-action insulin on the course of type 1 DM in 100 children and adolescents was studied. It was applied as basal-bolus regimen of insulin therapy. Analysis of parameters which reflect criteria of insulin therapy effectiveness, positive effect of ultra-rapid insulin analog on the course of DM has been performed. Results. Application of ultra-rapid insulin analog before each meal improved parameters of pre- and postprandial glycemia, decreased the range of fluctuations of blood sugar during the day, reduced and maintained HbA1c level without augmentation of frequency and intensity of hypoglycaemia, and also decreased the level of noctural hypoglycaemia. Conclusions. The ultra-rapid insulin analog is the drug of choice for the effective use in insulin pumps.


Keywords


type 1 diabetes mellitus; children and adolescents; basal-bolus regimen of insulin therapy; ultra-rapid insulin analog; glycemic control; insulin pump

References


Williams G, Paul SP, Hicks S. Diabetes in children. Adjusting to normal life as a diabetic. J Fam Health Care. 2012 Dec;22(6):16-7,19-22. PMID: 23342705.

Anishhenko OV, editor. Statystychno-analitychnyj dovidnyk dytjachogo endokrynologa za 2009 rik [Statistical and analytical guide of children's endocrinologist for 2009]. Kyiv; 2010. 101 p. (in Ukrainian).

Zelins'ka NB, Rudenko NG, authors. Tereshhenko AV, Golubchykov MV, editors. Statystychno-analitychnyj dovidnyk dytjachogo endokrynologa za 2013 rik [Statistical and analytical guide of children's endocrinologist for 2013]. Kyiv; 2014. 100 p. (in Ukrainian).

Zelins'ka NB, Rudenko NG, authors. Tereshhenko AV, Golubchykov MV, editors. Statystychno-analitychnyj dovidnyk dytjachogo endokrynologa za 2016 rik [Statistical and analytical guide of children's endocrinologist for 2016]. Kyiv; 2017. 102 p. (in Ukrainian).

Acharjee S, Ghosh B, Al-Dhubiab BE, Nair AB. Understanding type 1 diabetes: etiology and models. Can J Diabetes. 2013 Aug;37(4):269-76. doi: 10.1016/j.jcjd.2013.05.001.

Tillotson CV, Boktor SW. Diabetes mellitus, type 2, pediatric. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2017-2017 May 18. PMID: 28613700.

Zak KP, Popova VV. The prediction of type 1 diabetes development and diagnosis of its asymptomatic phase using autoantibodies to human islet of Langerhans long before the onset of the disease. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2016;7(9):11-21. doi: 10.22141/2224-0721.7.79.2016.86414. (in Ukrainian).

Danne Т, Becker D. Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes. Acta Paediatr. 2007 Nov;96(11):1560-70. doi: 10.1111/j.1651-2227.2007.00494.x.

Körner A. Diabetes mellitus in children. Orv Hetil. 2005 Jun 19;146(25):1335-43. PMID: 16106756.

Levesque C. Management of diabetes in children and adolescents. Nurs Clin North Am. 2017 Dec;52(4):589-603. doi: 10.1016/j.cnur.2017.07.008.

Hamilton H, Knudsen G, Vaina CL, Smith M, Paul SP. Children and young people with diabetes: recognition and management. Br J Nurs. 2017 Mar 23;26(6):340-347. doi: 10.12968/bjon.2017.26.6.340.

Raisingani M, Preneet B, Kohn B, Yakar S. Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis. Growth Horm IGF Res. 2017 Jun;34:13-21. doi: 10.1016/j.ghir.2017.04.003.

Malik FS, Taplin CE. Insulin therapy in children and adolescents with type 1 diabetes. Paediatr Drugs. 2014 Apr;16(2):141-50. doi: 10.1007/s40272-014-0064-6.

Choby B. Diabetes Update: Primary Care of Patients With Type 1 DiabetesFP Essent. 2017 May;456:11-19. PMID: 28530380.

Bolshova OV. Hypoglycemic states in children and adolescents. Clinical endocrinology and endocrine surgery. 2011;3:3-14. (in Ukrainian).

Bolshova OV, Samson OJa. The experience of prolonged use of analogues of insulin Epidra and Lantus in children and adolescents with type 1 diabetes mellitus. Ukrainian journal of pediatric endocrinology. 2012;1:14-18. (in Ukrainian).

Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014 Oct;127(10 Suppl):S25-38. doi: 10.1016/j.amjmed.2014.07.005.

Shalitin S, Peter Chase H. Diabetes technology and treatments in the paediatric age group. Int J Clin Pract Suppl. 2011 Feb;(170):76-82. doi: 10.1111/j.1742-1241.2010.02582.x.

Sprynchuk NA, Bolshova OV. Contemporary technologies in the treatment of type 1 diabetes in children. Endokrynologia. 2013;18(3):81-83. (in Ukrainian).

Karges B, Schwandt A, Heidtmann B, et al. Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017 Oct 10;318(14):1358-1366. doi: 10.1001/jama.2017.13994.

Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016 Jan;32(1):21-39. doi: 10.1002/dmrr.2653.

Skyler JS, Ponder S, Kruger DF, Matheson D, Parkin ChG. Is there a place for insulin pumps therapy in your practice? Clinical Diabetes 2007 Apr;25(2):50-56. doi: 10.2337/diaclin.25.2.50.

Golden SH, Sapir T. Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review. J Manag Care Pharm. 2012 Aug;18(6 Suppl):S1-17. PMID: 22984955.

Melidonis A, Kamaratos A, Angelidi A, et al. The impact of continuous subcutaneous insulin infusion therapy on efficacy and safety in a cohort of type 1 diabetes patients: A 3-year prospective study. Diabetes Technol Ther. 2016 Mar;18(3):159-63. doi: 10.1089/dia.2015.0309.

Danne T, Bangstad HJ, Deeb L, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2014 Sep;15 Suppl 20:115-34. doi: 10.1111/pedi.12184.

Galli-Tsinopoulou A, Stergidou D. Insulin analogues for type 1 diabetes in children and adolescents. Drugs Today (Barc). 2012 Dec;48(12):795-809. doi: 10.1358/dot.2012.48.12.1872944.

Lih A, Hibbert E, Wong T, Girgis CM, Garg N, Carter JN. The role of insulin glulisine to improve glycemic control in children with diabetes mellitus. Diabetes Metab Syndr Obes. 2010 Nov 26;3:403-12. doi: 10.2147/DMSOTT.S5116.

Garg S, Ampudia-Blasco FJ, Pfohl M. Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus.

Zelins'ka NB. Unified clinical protocol of emergency, primary, secondary (specialized) and tertiary (highly specialized) health care «diabetes mellitus type 1 in children». Part 2. Ukrainian journal of pediatric endocrinology. 2016;4(20):34-86. (in Ukrainian ).

Bolshova OV, Samson OJa. The use of an analogue of insulin Lantus in the treatment of diabetes mellitus in children and adolescents. Problemi endokrinnoi patologii. 2005;3:9-14. (in Ukrainian).

Bolshova OV, Samson OJa. 10 years of the Lantus drug in Ukraine: domestic and foreign experience in the use of insulin glargine in the treatment of diabetes mellitus. Ukrainian Medical Journal. 2014;2:49-52. (in Ukrainian).

Konstantinova M, Loizeau V, Pilorget V, Cali A, Danne T. Safety results from OCAPI: a European Observational Cohort Study of insulin glulisine-treated children aged 6-12 years with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2014 Oct;122(9):523-7. doi: 10.1055/s-0034-1377005.

Garnock-Jones KP, Plosker GL. Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009 May 29;69(8):1035-57. doi: 10.2165/00003495-200969080-00006.

Wong JC, Boyle C, DiMeglio LA, et al. Evaluation of pump discontinuation and associated factors in the T1D exchange clinic registry. J Diabetes Sci Technol. 2017 Mar;11(2):224-232. doi: 10.1177/1932296816663963.

Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016 Jan;32(1):21-39. doi: 10.1002/dmrr.2653.

Benkhadra K, Alahdab F, Tamhane SU, McCoy RG, Prokop LJ, Murad MH. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2017 Jan;55(1):77-84. doi: 10.1007/s12020-016-1039-x.

Urakami T, Mine Y, Aoki M, Okuno M, Suzuki J. Insulin glulisine for continuous subcutaneous insulin infusion in pediatric type 1 diabetes. Pediatr Int. 2017 May;59(5):647-649. doi: 10.1111/ped.13271.

Naik S, Kerr D, Begley J, Morton J. Influence of local skin temperature and choice of insulin analog on catheter occlusion rates during continuous insulin infusion: an exploratory study. Diabetes Technol Ther. 2012 Nov;14(11):1018-22. doi: 10.1089/dia.2012.0080.

Heinemann L, Fleming GA, Petrie JR, Holl RW, Bergenstal RM, Peters AL. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting and research needs. A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetologia. 2015 May;58(5):862-70. doi: 10.1007/s00125-015-3513-z.




DOI: https://doi.org/10.22141/2224-0721.13.8.2017.119273

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта